124 related articles for article (PubMed ID: 17008891)
1. Do RARA/PML fusion gene deletions confer resistance to ATRA-based therapy in patients with acute promyelocytic leukemia?
Subramaniyam S; Nandula SV; Nichols G; Weiner M; Satwani P; Alobeid B; Bhagat G; Murty VV
Leukemia; 2006 Dec; 20(12):2193-5. PubMed ID: 17008891
[No Abstract] [Full Text] [Related]
2. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
[TBL] [Abstract][Full Text] [Related]
3. All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene.
Strehl S; König M; Boztug H; Cooper BW; Suzukawa K; Zhang SJ; Chen HY; Attarbaschi A; Dworzak MN
Leukemia; 2013 Jul; 27(7):1606-10. PubMed ID: 23271512
[No Abstract] [Full Text] [Related]
4. PML-RARalpha ligand-binding domain deletion mutations associated with reduced disease control and outcome after first relapse of APL.
Schachter-Tokarz E; Kelaidi C; Cassinat B; Chomienne C; Gardin C; Raffoux E; Dombret H; Fenaux P; Gallagher R
Leukemia; 2010 Feb; 24(2):473-6. PubMed ID: 19865110
[No Abstract] [Full Text] [Related]
5. Autophagic degradation of an oncoprotein.
Bøe SO; Simonsen A
Autophagy; 2010 Oct; 6(7):964-5. PubMed ID: 20724820
[TBL] [Abstract][Full Text] [Related]
6. The short isoform of the long-type PML-RARA fusion gene in acute promyelocytic leukaemia lacks sensitivity to all-trans-retinoic acid.
Tan Y; Bian S; Xu Z; Chen X; Qi X; Ren F; Li L; Guo H; Xu A; Zhang L; Wang H
Br J Haematol; 2013 Jul; 162(1):93-7. PubMed ID: 23627671
[TBL] [Abstract][Full Text] [Related]
7. A unique case of acute promyelocytic leukemia showing monocytic differentiation after ATRA (all-trans retinoic acid) therapy.
Naeem M; Harrison K; Barton K; Nand S; Alkan S
Eur J Haematol; 2006 Feb; 76(2):164-6. PubMed ID: 16405439
[TBL] [Abstract][Full Text] [Related]
8. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
Grimwade D; Mistry AR; Solomon E; Guidez F
Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
[TBL] [Abstract][Full Text] [Related]
9. Identification of the novel deletion-type PML-RARA mutation associated with the retinoic acid resistance in acute promyelocytic leukemia.
Hattori H; Ishikawa Y; Kawashima N; Akashi A; Yamaguchi Y; Harada Y; Hirano D; Adachi Y; Miyao K; Ushijima Y; Terakura S; Nishida T; Matsushita T; Kiyoi H
PLoS One; 2018; 13(10):e0204850. PubMed ID: 30289902
[TBL] [Abstract][Full Text] [Related]
10. Therapy-related myeloproliferative neoplasm with ETV6-PDGFRB rearrangement following treatment of acute promyelocytic leukemia.
Malfuson JV; Konopacki J; Fagot T; Desangles F; Bories D; Souleau B; de Revel T
Ann Hematol; 2011 Dec; 90(12):1477-9. PubMed ID: 21350831
[No Abstract] [Full Text] [Related]
11. The co-expression of PML/RAR alpha and AML1/ETO fusion genes is associated with ATRA resistance.
Abreu e Lima RS; Baruffi MR; de Lima AS; de Oliveira FM; de Figueiredo-Pontes LL; Tone LG; Rogatto SR; Falcao RP; Ferrari Chauffaille Mde L; Rego EM
Br J Haematol; 2005 Feb; 128(3):407-9. PubMed ID: 15667548
[No Abstract] [Full Text] [Related]
12. [All-trans retinoic acid therapy in acute promyelocytic leukemia--current status and prospect].
Kitamura K; Takeshita A; Ono R; Naoe T
Rinsho Ketsueki; 1996 Sep; 37(9):760-5. PubMed ID: 8914458
[No Abstract] [Full Text] [Related]
13. Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells.
Guo W; Wang H; Zhao W; Zhu J; Ju B; Wang X
Chin Med J (Engl); 2001 Jan; 114(1):30-4. PubMed ID: 11779431
[TBL] [Abstract][Full Text] [Related]
14. Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid. The Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho).
Fukutani H; Naoe T; Ohno R; Yoshida H; Miyawaki S; Shimazaki C; Miyake T; Nakayama Y; Kobayashi H; Goto S
Leukemia; 1995 Sep; 9(9):1478-82. PubMed ID: 7658715
[TBL] [Abstract][Full Text] [Related]
15. [Acute promyelocytic leukemia, histone deacetylase, and response to retinoids].
Jeanteur P
Bull Cancer; 1998 Apr; 85(4):301-3. PubMed ID: 9752292
[TBL] [Abstract][Full Text] [Related]
16. Molecular cytogenetics of the acute promyelocytic leukemia-derived cell line NB4 and of four all-trans retinoic acid-resistant subclones.
Mozziconacci MJ; Rosenauer A; Restouin A; Fanelli M; Shao W; Fernandez F; Toiron Y; Viscardi J; Gambacorti-Passerini C; Miller WH; Lafage-Pochitaloff M
Genes Chromosomes Cancer; 2002 Nov; 35(3):261-70. PubMed ID: 12353268
[TBL] [Abstract][Full Text] [Related]
17. Resistance to therapy in acute promyelocytic leukemia.
Lehmann-Che J; Bally C; de Thé H
N Engl J Med; 2014 Sep; 371(12):1170-2. PubMed ID: 25229938
[No Abstract] [Full Text] [Related]
18. Identification of a novel PML-RARG fusion in acute promyelocytic leukemia.
Ha JS; Do YR; Ki CS; Lee C; Kim DH; Lee W; Ryoo NH; Jeon DS
Leukemia; 2017 Sep; 31(9):1992-1995. PubMed ID: 28555082
[No Abstract] [Full Text] [Related]
19. Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy.
Breccia M; Stefania de Propris M; Molica M; Colafigli G; Minotti C; Diverio D; Latagliata R; Guarini A; Lo-Coco F; Foà R
Am J Hematol; 2015 Sep; 90(9):E181-2. PubMed ID: 26119985
[No Abstract] [Full Text] [Related]
20. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
Vitoux D; Nasr R; de The H
Int J Biochem Cell Biol; 2007; 39(6):1063-70. PubMed ID: 17468032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
